2011 - 10th Meeting - IHCTAS


This page contains exclusive content for the member of the following sections: TTS, IHCTAS. Log in to view.

Posters

2.5 - OUTCOME 5 YEARS AFTER THE FIRST HUMAN PARTIAL FACE TRANSPLANTATION

Presenter: Palmina, Petruzzo, Lyon, France
Authors: Palmina Petruzzo, Sylvie Testelin, Emmanuel Morelon, Lionel Badet, Jean Michel Dubernard, Jean Kanitakis, Maria Brunet, Benoit Lengele, Bernard Devauchelle

OUTCOME 5 YEARS AFTER THE FIRST HUMAN PARTIAL FACE TRANSPLANTATION

Palmina Petruzzo1, Sylvie Testelin2, Emmanuel Morelon1, Lionel Badet1, Jean Michel Dubernard1, Jean Kanitakis1, Maria Brunet1, Benoit Lengele3, Bernard Devauchelle2.

1Dept of Transplantation Hospices Civils de Lyon, Lyon, France; 2Dept of Maxillofacial Surgery University Hospital of Amiens, Amiens, France; 3Experimental Morphology Department, Catholic University of Louvain, Brussels, Belgium.

Aim of the study was to estimate the aesthetic aspect and functional recovery of the facial graft and the risk to benefit ratio 5 years after the first human facial transplantation (Tx), which consisted of nose, chip and lips.

The initial immunosuppressive protocol included tacrolimus, mycophenolate mofetil, prednisone and antithymocyte globulins. In addition, donor bone marrow (BM) cells were infused on days 4 and 11 after Tx.

Aesthetic and functional recovery was satisfying. She has normal pain and cold sensation. Discriminativerecovery was normal since 2 years after Tx. The analysis of motion recovery showed a rapid improvement of muscle function. After the first year she presented a normal mouth opening, and labial closure is complete despite a persisting light asymmetry. She can smile, chew, swallow and blow normally while pouting and kissing is still difficult. Phonation recovery was impressive and the patient can talk normally.

She presented only two episodes of acute rejection in the first year. Microchimerism was not detected in peripheral blood but was observed in CD34+ BM cells 2 months after Tx. Donor specific anti-HLA antibodies were never detected. Five-year protocol mucosal biopsy showed a slight perivascular infiltrate while skin biopsy was normal.

The main side effect of the immunosuppressive regimen was a progressive decrease in renal function 11 post-tx months that improved after the switch from tacrolimus to sirolimus. In addition, she developed chronic hypertension and increase in lipid levels which were pharmacologically well controlled. Because of an increase in Gamma-GT values a hepatic biopsy was performed showing focal mild biliary lesions and a very slight peri-portal inflammatory infiltrate and no alterations of biliary tree.

Although the reported long-term complications, which are similar to those reported in solid organ transplantation, the patient is very satisfied of her new face and has normal social interaction.


Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.

Social

Contact

Staff Directory
+1-514-874-1717
info@tts.org

Address

The Transplantation Society
International Headquarters
740 Notre-Dame Ouest
Suite 1245
Montréal, QC, H3C 3X6
Canada